The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $33.93, representing a -2.5% change from its previous close.

SG Americas Securities LLC lessened its holdings in shares of Viking Therapeutics, Inc. (NASDAQ: VKTX) by 27.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 69,613 shares of the biotechnology company's stock after selling 26,191 shares during the period. SG

Defensive healthcare stocks such as Johnson & Johnson and CVS tend to outperform in recessions. Growth healthcare stocks offer higher risk and potential reward, less tied to economic cycles.

Viking Therapeutics has a shot at becoming a leader in the weight-loss market. However, the company's quest could run into significant obstacles.

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative asset.

There are some tempting bargains if you know where to look.

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.94, indicating a -7.95% shift from the previous trading day.

Viking Therepeutics' VK2735 candidate is a dark horse contender among GLP-1 weight loss drugs. If upcoming late-stage clinical trial results prove positive, Viking's value as a takeover target could rise exponentially.

Viking Therapeutics climbs after it completes enrollment in the second phase III obesity study for VK2735 and advances its bid in a fast-growing, competitive weight-loss market.

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.